Kenvue
Consumer health · United States
Kenvue, spun off from Johnson & Johnson in 2023, sells consumer health brands such as Tylenol, Neutrogena, Listerine, Band-Aid, Aveeno and Zyrtec in more than 165 countries, and is being acquired by Kimberly-Clark.
What makes it different
Medicine-cabinet brands that once belonged to J&J.
42.2%Net sales from Self Care medicinesFY2025
Tylenol, Band-Aid and Listerine came from Johnson & Johnson, which spun Kenvue off in 2023.
How big it is
How big is Kenvue?
$15.1BNet salesFY2025
165+CountriesFY2025
22,000Employees2025
How it makes money FY2025
Medicines, skin care and everyday essentials.
- Self Care42%$6.38B
- Essential Health31%$4.63B
- Skin Health and Beauty27%$4.11B
How the business works
Doctor-trusted brands on every shelf.
- 1Clinically tested formulas
- 2Doctor and pharmacist recommendations
- 3Through retailers worldwide
Health-professional endorsement lets Kenvue charge more than store brands for similar ingredients.
Who owns it
- The Vanguard Group12.15%
- BlackRock, Inc.6.72%
- State Street Corporation6.63%
CEO: Kirk L. Perry
Who it competes with
Key moments
- 2021J&J plans consumer health spin-off
- 2022Kenvue incorporated
- 2023IPO on the NYSE
- 2023J&J exchange offer completes separation
- 2025Kirk Perry named interim CEO
Sources
Every number on this page comes from Kenvue's own reports.
Full profile
The rest of the story is in the app.
What Kenvue tracks17 metrics
Countries where products are marketed
Scientists, doctors, pharmacists and engineers
Employees
Results, quarter by quarterwith a chart
Revenue
Profit
Margin
The full timeline15 moments
2024
2025
2026
Kenvue vs Haleonside by side
Revenue
Profit
People
Point your phone at a logo.
See the company behind it.
The full story in 12 chapters · compare any two companies · 335 companies, and any other on request.
Download on the App Store
